These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 33035201)

  • 1. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.
    Zeng C; Evans JP; Pearson R; Qu P; Zheng YM; Robinson RT; Hall-Stoodley L; Yount J; Pannu S; Mallampalli RK; Saif L; Oltz E; Lozanski G; Liu SL
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33035201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay.
    Zeng C; Evans JP; Pearson R; Qu P; Zheng YM; Robinson RT; Hall-Stoodley L; Yount J; Pannu S; Mallampalli RK; Saif L; Oltz E; Lozanski G; Liu SL
    medRxiv; 2020 Aug; ():. PubMed ID: 32793931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
    Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
    J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
    Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
    Viruses; 2021 May; 13(5):. PubMed ID: 34065987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.
    Gharbharan A; Jordans CCE; GeurtsvanKessel C; den Hollander JG; Karim F; Mollema FPN; Stalenhoef-Schukken JE; Dofferhoff A; Ludwig I; Koster A; Hassing RJ; Bos JC; van Pottelberge GR; Vlasveld IN; Ammerlaan HSM; van Leeuwen-Segarceanu EM; Miedema J; van der Eerden M; Schrama TJ; Papageorgiou G; Te Boekhorst P; Swaneveld FH; Mueller YM; Schreurs MWJ; van Kampen JJA; Rockx B; Okba NMA; Katsikis PD; Koopmans MPG; Haagmans BL; Rokx C; Rijnders BJA
    Nat Commun; 2021 May; 12(1):3189. PubMed ID: 34045486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses.
    Schlickeiser S; Schwarz T; Steiner S; Wittke K; Al Besher N; Meyer O; Kalus U; Pruß A; Kurth F; Zoller T; Witzenrath M; Sander LE; Müller MA; Scheibenbogen C; Volk HD; Drosten C; Corman VM; Hanitsch LG
    Front Immunol; 2020; 11():628971. PubMed ID: 33584731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
    Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA
    mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.
    Oguntuyo KY; Stevens CS; Hung CT; Ikegame S; Acklin JA; Kowdle SS; Carmichael JC; Chiu HP; Azarm KD; Haas GD; Amanat F; Klingler J; Baine I; Arinsburg S; Bandres JC; Siddiquey MNA; Schilke RM; Woolard MD; Zhang H; ; Duty AJ; Kraus TA; Moran TM; Tortorella D; Lim JK; Gamarnik AV; Hioe CE; Zolla-Pazner S; Ivanov SS; Kamil JP; Krammer F; Lee B
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 evolution during treatment of chronic infection.
    Kemp SA; Collier DA; Datir RP; Ferreira IATM; Gayed S; Jahun A; Hosmillo M; Rees-Spear C; Mlcochova P; Lumb IU; Roberts DJ; Chandra A; Temperton N; ; ; Sharrocks K; Blane E; Modis Y; Leigh KE; Briggs JAG; van Gils MJ; Smith KGC; Bradley JR; Smith C; Doffinger R; Ceron-Gutierrez L; Barcenas-Morales G; Pollock DD; Goldstein RA; Smielewska A; Skittrall JP; Gouliouris T; Goodfellow IG; Gkrania-Klotsas E; Illingworth CJR; McCoy LE; Gupta RK
    Nature; 2021 Apr; 592(7853):277-282. PubMed ID: 33545711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay.
    Janaka SK; Clark NM; Evans DT; Mou H; Farzan M; Connor JP
    PLoS One; 2021; 16(7):e0253551. PubMed ID: 34310603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
    Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma.
    Wang L; Zhao J; Nguyen LNT; Adkins JL; Schank M; Khanal S; Nguyen LN; Dang X; Cao D; Thakuri BKC; Lu Z; Zhang J; Zhang Y; Wu XY; El Gazzar M; Ning S; Moorman JP; Yao ZQ
    Sci Rep; 2021 Mar; 11(1):5558. PubMed ID: 33692386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.